Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Medication research papers
Efficacy & safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's dementi
Cholinesterase inhibitors and memantine slightly improve global impression; however, only cholinesterase inhibitors enhance cognitive function. Besides, all the drugs have good safety outcomes. But the limited trials precluded the generalisation of these outcomes.
14 May 2014
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease
Conclusions: The present results provide convincing evidence that presynaptic dopaminergic denervation in PD plays a crucial role in the development of LID.
06 May 2014
Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
This review focuses on the principle of LCIG infusion therapy and gives a comprehensive summary of the existing data on therapeutic effects and adverse events and possible complications.
02 May 2014
The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model
Conclusion: Daily administration of a SP NK1 receptor antagonist may represent a novel treatment regime that reduces the onset of LID whilst conserving motor function.
01 May 2014
Long-term safety & sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
These results support the long-term safety and efficacy of pramipexole ER in early and advanced PD. AEs were typical for dopaminergic medications, and UPDRS scores suggested sustained symptomatic benefit.
01 May 2014
Effect of nicotine on l-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis
Authors conclude that nicotine appears to have efficacy in animal models of LID. Large randomized clinical trials testing the effect of nicotine in PD patients with LID are warranted.
01 May 2014
Early Versus Delayed Initiation of Pharmacotherapy in Parkinson's Disease
Although the data on putative disease-modifying effects of early pharmacological intervention in PD are still inconclusive, authors believe that the most important indication for an early initiation of anti-parkinsonian treatment should be to maintain the quality of life of PD patients and to secure their socioeconomic status as long as possible.
23 April 2014
Another face of placebo: The lessebo effect in Parkinson disease
This study shows that the use of a placebo can be associated with a clinically significant reduction in the magnitude of change of the mUPDRS after an active treatment in RCTs for PD. These new findings have potential implications in the development of new treatments and appraisal of current treatment options for PD and possibly for other neurologic disorders.
22 April 2014
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease
The nAChR drugs did not worsen parkinsonism or cognitive ability. Emesis, a common problem with nAChR drugs, was not observed. ABT-894 and ABT-089 appear to be good candidate nAChR drugs for the management of LIDs in Parkinson's disease.
15 April 2014
The effect of medication and the role of postural instability in different components of freezing of gait (FOG)
The improvement of FOG frequency and duration but not of gait asymmetry and arrhythmicity on meds suggests that both dopaminergic and non-dopaminergic networks contribute to FOG. The correlations between postural instability and FOG severity and SIP asymmetry on meds, suggest that as the disease progresses, postural instability interferes with gait symmetry and lead to on meds FOG and falls.
01 April 2014
Back to Top
Add page to PDF basket
Copyright © 2015 EPDA. All Rights Reserved.
Privacy and cookies